Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,326

Mesenchymal stem cells (MSCs) have been a topic of great interest in the last decade or so due to their ability to improve tissue regeneration merely by their presence and the secreted signals they give out.

Adult MSCs have traditionally been used for regenerative medicine with hit-and-miss results, depending on the quality and age of the harvested MSCs. It has been discovered in recent years that the efficacy of these cells greatly depends on how damaged by aging they are, which explains why MSC therapy sometimes works very well in one person but not so much in another.

However, what about aged cells that are reprogrammed back to pluripotency then guided into becoming mesenchymal stem cells through cellular reprogramming?

Read more

Earlier this year, we launched a new webinar series where our monthly patrons, the Lifespan Heroes, are given the opportunity to join live discussion panels with the researchers who are working on solving aging.

Our April 8th, 2019 episode saw Dr. Mike Lustgarten, Dr. Amy Proal, and Dr. Cosmo Mielke join hosts Dr. Oliver Medvedik and Steve Hill for a discussion about the microbiome and how it relates to aging.

The webinar discusses gut flora and the pro-aging effects of immune system burden, the link between bacterial burden and inflammation, and exercise and nutrition. There was also plenty of discussion about the immediately available practical measures that can improve the gut microbiome and thus control weight and promote health.

Read more

Background: The medical agent #MK615 is produced from #JapaneseApricot and contains a number of cyclic triterpenes. Antitumor activity of MK615 and its additive effect when combined with gemcitabine in pancreatic cancer cell line. MIAPaCa-2 was previously reported by our group. The objective of this phase I trial was to evaluate safety and feasibility of combined MK615 and gemcitabine therapy in patients with advanced or metastatic pancreatic cancer.

Conclusions: Combined MK615 and gemcitabine therapy was well-tolerated and showed antitumor activity in patients previously treated without gemcitabine or untreated patients with advanced or metastatic pancreatic cancer. Currently, we are planning phase II trials for elderly or frail people.

510

Background: The medical agent MK615 is produced from Japanese apricot and contains a number of cyclic triterpenes. Antitumor activity of MK615 and its additive effect when combined with gemcitabine in pancreatic cancer cell line. MIAPaCa-2 was previously reported by our group. The objective of this phase I trial was to evaluate safety and feasibility of combined MK615 and gemcitabine therapy in patients with advanced or metastatic pancreatic cancer. Methods: Patients with untreated pancreatic cancer or those who underwent chemotherapy without gemcitabine were enrolled. Gemcitabine was infused at 1000 mg/m2 over 30 minutes once weekly for 3 weeks of each 28-day treatment cycle. Three packets of MK615 were orally administered daily during each 28-day treatment cycle, until any discontinuation criteria were met. If severe toxicity occurred, dose was reduced. Results: All five patients enrolled were evaluable for toxicity and response. Median age was 72 (54−79) years. Three patients had performance status (PS) 0, one had PS 1, and one PS 2. Three of five patients had been treated with chemotherapy; two with FOLFIRINOX and one with S-1. One of five patients treated had grade 4 neutropenia and two were administered granulocyte-colony stimulating factor. No patient had febrile neutropenia or adverse event leading to death. Relative dose intensity was 96.6% and 69.8% for MK615 and gemcitabine, respectively. No patients had objective response (complete response + partial response), while 2 of 5 patients (40%) had disease control (objective response + stable disease). Conclusions: Combined MK615 and gemcitabine therapy was well-tolerated and showed antitumor activity in patients previously treated without gemcitabine or untreated patients with advanced or metastatic pancreatic cancer. Currently, we are planning phase II trials for elderly or frail people.

Read more

Arab American University congrats and is proud of Dr. Thabat Al-Khatib and researcher in Applied Neuroscience, Dr. Al-Khatib graduated from the Faculty of Sciences and Arts at Arab American University in 2012. She succeeded to add her name on the list of innovators in Britain after the invention of a drug treatment for Alzheimer’s disease and received two patents.

Al Khatib is currently working at the University of Aberdeen – Faculty of Medicine as a researcher in Neuroscience dept. and aspires to be a lecturer in Palestine to add value to students and the community.

Al-Khatib said commenting on the two inventions:

Read more

Patients recovering from a stroke can slash their risk of blood clots by wearing a small “half wrist-watch” around their leg, a trial has shown.

A study at Royal Stoke University Hospital found the geko device could reduces the risk of clots compared to standard treatment, is comfortable to wear and could save the NHS cash.

Approved for use on the NHS for other conditions, the geko is a battery-powered, disposable, device designed to increase blood flow in the deep veins of the legs.

Read more